- Home
- UTL vs PHAT Comparison
UTL vs PHAT Comparison
Compare UTL & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | UTL | PHAT |
|---|---|---|
| Founded | 1984 | 2018 |
| Country | United States | United States |
| Employees | N/A | 371 |
| Industry | Power Generation | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 906.9M | 969.8M |
| IPO Year | 1995 | 2019 |
Fundamental Metrics
Financial Performance| Metric | UTL | PHAT |
|---|---|---|
| Price | $52.85 | $12.47 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | ★ $56.50 | $19.83 |
| AVG Volume (30 Days) | 131.0K | ★ 1.0M |
| Earning Date | 05-04-2026 | 04-30-2026 |
| Dividend Yield | ★ 3.65% | N/A |
| EPS Growth | 1.37 | ★ 42.72 |
| EPS | ★ 1.85 | N/A |
| Revenue | ★ $536,000,000.00 | $175,110,000.00 |
| Revenue This Year | $5.43 | $93.04 |
| Revenue Next Year | $4.22 | $58.91 |
| P/E Ratio | $28.48 | ★ N/A |
| Revenue Growth | 8.33 | ★ 216.93 |
| 52 Week Low | $45.11 | $7.61 |
| 52 Week High | $55.08 | $18.31 |
Technical Indicators
Market Signals| Indicator | UTL | PHAT |
|---|---|---|
| Relative Strength Index (RSI) | 55.99 | 67.90 |
| Support Level | $49.84 | $12.31 |
| Resistance Level | $53.69 | $13.26 |
| Average True Range (ATR) | 1.18 | 0.60 |
| MACD | 0.03 | 0.23 |
| Stochastic Oscillator | 70.52 | 98.60 |
Price Performance
Historical ComparisonAbout UTL UNITIL Corporation
Unitil Corp through its subsidiaries engages in the distribution of electricity and natural gas in its service territories in the states of New Hampshire, Massachusetts and Maine. Its natural gas operations include gas distribution utility operations and interstate gas transmission pipeline operations. It also engages in interstate natural gas transmission pipeline company, operating approximately 85 miles of underground gas transmission pipeline located in Maine and New Hampshire. The company's segments include Electric and Gas.
About PHAT Phathom Pharmaceuticals Inc.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.